Curated News
By: NewsRamp Editorial Staff
April 02, 2026

Soligenix's HyBryte Outperforms Valchlor in CTCL Study with 60% Success Rate

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Soligenix's HyBryte offers a significant advantage over Valchlor with 60% treatment success versus 20%, positioning it as a superior therapy for cutaneous T-cell lymphoma.
  • HyBryte works as a photodynamic therapy using synthetic hypericin and visible light, achieving 60% treatment success in 12 weeks with no reported adverse events in the study.
  • HyBryte's favorable safety profile and higher efficacy could improve quality of life for CTCL patients by providing a well-tolerated treatment with fewer adverse reactions.
  • HyBryte tripled treatment success rates compared to Valchlor in CTCL patients, using light-activated therapy with no adverse events reported in the published study.

Impact - Why it Matters

This news matters because cutaneous T-cell lymphoma is a rare and often debilitating cancer with limited treatment options, particularly for early-stage patients. HyBryte's superior efficacy and safety profile, as shown in the study, could revolutionize CTCL care by providing a more effective and better-tolerated therapy, potentially reducing side effects and improving patient quality of life. For the broader healthcare landscape, it highlights advancements in photodynamic therapy and rare disease research, offering hope for similar innovations in other conditions. Investors and stakeholders should note Soligenix's progress toward commercialization, which could enhance treatment accessibility and drive growth in the biopharmaceutical sector.

Summary

Soligenix (NASDAQ: SNGX) has announced groundbreaking results from its comparability study published in Oncology and Therapy, revealing that HyBryte™ significantly outperforms Valchlor® in treating cutaneous T-cell lymphoma (CTCL). The study demonstrated that after 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to just 20% for Valchlor, with HyBryte also showing greater average improvement. Notably, HyBryte reported no treatment-related adverse events, while Valchlor patients experienced multiple adverse reactions, positioning HyBryte as a potentially safer and more effective therapy for early-stage CTCL. This positive outcome supports Soligenix's efforts to seek regulatory approvals for worldwide commercialization of HyBryte, a novel photodynamic therapy using safe visible light.

Soligenix, a late-stage biopharmaceutical company, focuses on developing treatments for rare diseases with unmet medical needs through its Specialized BioTherapeutics business segment. Beyond HyBryte for CTCL, the company is expanding synthetic hypericin into psoriasis treatments and developing first-in-class innate defense regulator technology for inflammatory diseases like oral mucositis and Behçet's Disease. Their Public Health Solutions segment, supported by government funding from agencies like NIAID and BARDA, includes vaccine candidates for ricin toxin, filoviruses such as Marburg and Ebola, and CiVax™ for COVID-19 prevention, utilizing their proprietary ThermoVax® heat stabilization platform. For more details, the full press release is available at https://ibn.fm/Eq1BX, and updates on SNGX can be found in the company's newsroom at https://ibn.fm/SNGX, with disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.

The forward-looking statements in the release highlight potential risks and uncertainties, as outlined in Soligenix's SEC filings, but the comparability study's results underscore HyBryte's promise as a well-tolerated alternative in the CTCL treatment landscape. This development could address critical gaps in care for patients with this rare cancer, offering hope for improved outcomes and quality of life. As Soligenix advances toward regulatory submissions, the oncology community and investors are closely watching, given the company's broader pipeline targeting other rare and infectious diseases. The integration of anchor text keywords like "NEWMEDIAWIRE" and links to resources ensures transparency and access to further information, reinforcing the news's credibility and impact.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Soligenix's HyBryte Outperforms Valchlor in CTCL Study with 60% Success Rate

blockchain registration record for this content.